Yahoo · Aug 13, 2026
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
NYSE · BAX
Baxter International Inc.
Healthcare · Medical - Instruments & Supplies
$25.94
Up+$0.03 (+0.12%)
Updated Aug 19, 2026, 8:31 AM
SID Score
6.5/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 9.71B
- P/E ratio
- -28.49
- Dividend yield
- 2.00%
- 52-week range
- $15.73 – $30.00
- Volume
- 6.69M
- Avg. volume
- 7.88M
Price performance
BAX price history
1M range · 21 trading sessions · Daily adjusted prices
BAX closed at $25.94 after 21 trading sessions, up 16.79% for the selected period.
- Last close
- $25.94
- Period change
- +16.79%
- Period low
- $21.67
- Period high
- $28.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $26.08 | $26.335 | $25.75 | $25.94 | 6.69M |
| Aug 17, 2026 | $26.47 | $26.47 | $25.865 | $25.91 | 5.85M |
| Aug 14, 2026 | $27.01 | $27.16 | $26.595 | $26.73 | 4.96M |
| Aug 13, 2026 | $27.02 | $27.45 | $26.895 | $27.05 | 6.71M |
| Aug 12, 2026 | $27.20 | $27.40 | $26.64 | $26.95 | 6.88M |
| Aug 11, 2026 | $27.55 | $28.015 | $27.38 | $27.61 | 7.58M |
| Aug 10, 2026 | $27.12 | $27.97 | $26.78 | $27.78 | 8.31M |
| Aug 7, 2026 | $26.93 | $27.88 | $26.56 | $27.55 | 8.16M |
| Aug 6, 2026 | $27.41 | $27.95 | $26.815 | $27.01 | 6.94M |
| Aug 5, 2026 | $28.20 | $28.21 | $27.09 | $27.33 | 9.3M |
| Aug 4, 2026 | $27.74 | $28.375 | $27.48 | $28.35 | 10.21M |
| Aug 3, 2026 | $26.98 | $28.30 | $26.90 | $28.10 | 10.45M |
| Jul 31, 2026 | $26.92 | $27.145 | $26.025 | $26.16 | 9.28M |
| Jul 30, 2026 | $29.07 | $30.00 | $26.045 | $26.75 | 22.67M |
| Jul 29, 2026 | $24.40 | $24.925 | $24.28 | $24.77 | 9.43M |
| Jul 28, 2026 | $23.85 | $24.75 | $23.575 | $24.37 | 7.1M |
| Jul 27, 2026 | $22.68 | $23.395 | $22.60 | $23.34 | 5.45M |
| Jul 24, 2026 | $21.95 | $22.645 | $21.895 | $22.40 | 4.98M |
| Jul 23, 2026 | $21.56 | $21.78 | $21.40 | $21.67 | 4.52M |
| Jul 22, 2026 | $22.53 | $22.5599 | $21.70 | $21.74 | 4.51M |
| Jul 21, 2026 | $21.86 | $22.24 | $21.84 | $22.21 | 3.96M |
Latest BAX news
The latest Smart Investors Daily articles mentioning BAX.
Stock researchCompany · Overview
BAX research
Overview
Company profile and research snapshot.
Company profile
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | Stifel | Hold | — |
| Jul 31, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
| Jul 28, 2026 | UBS | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
Does Cardinal Health’s New CAO and Recalls Reveal Shifts in Its Risk Profile and Earnings Quality (CAH)?
In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...
Benzinga · Aug 4, 2026
Baxter International Says Anita Zielinski To Resign As Interim CFO, Effective September 15, 2026
-SEC Filing
Fintel · Aug 4, 2026
Baxter International (BAX) Price Target Increased by 25.96% to 27.05
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
